AKT is a therapeutic target in myeloproliferative neoplasms
Open Access
- 10 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (9), 1882-1890
- https://doi.org/10.1038/leu.2013.167
Abstract
The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN and are associated with hematopoietic toxicities. MK-2206 is a potent allosteric AKT inhibitor that was well tolerated, including no evidence of myelosuppression, in a phase I study of solid tumors. Herein, we show that inhibition of PI3K/AKT signaling by MK-2206 affected the growth of both JAK2V617F- or MPLW515L-expressing cells via reduced phosphorylation of AKT and inhibition of its downstream signaling molecules. Moreover, we demonstrate that MK-2206 synergizes with ruxolitinib in suppressing the growth of JAK2V617F-mutant SET2 cells. Importantly, MK-2206 suppressed colony formation from hematopoietic progenitor cells in patients with primary myelofibrosis and alleviated hepatosplenomegaly and reduced megakaryocyte burden in the bone marrows, livers and spleens of mice with MPLW515L-induced MPN. Together, these findings establish AKT as a rational therapeutic target in the MPNs.Keywords
This publication has 59 references indexed in Scilit:
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013
- MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and ApoptosisMolecular Cancer Therapeutics, 2012
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansJCI Insight, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseBlood, 2010
- Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activationExperimental Hematology, 2009
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsJCI Insight, 2008
- Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosisBlood, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005